{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:27:39Z","timestamp":1760502459738,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Early response of the primary tumor (PT) to neoadjuvant chemotherapy (NAC) in patients with esophageal squamous cell carcinoma (ESCC) is considered a potential predictor of postoperative prognosis. However, the role of metastatic lymph nodes (LNs) remains poorly understood. This study aimed to compare the predictive value of early response in PT and LNs for postoperative prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We enrolled 124 consecutive patients who received NAC-docetaxel, cisplatin, 5-fluorouracil (DCF) followed by surgery for ESCC between April 2010 and March 2020. Initial tumor reduction of the PT (ITR-PT) and LN (ITR-LN), defined as the percentage decrease in tumor shorter diameter after the first course of NAC-DCF, was evaluated using computed tomography. The optimal cut-off values of ITRs were determined using receiver operating characteristic curves and Cox regression models, and their relationship with recurrence-free survival (RFS) was analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median ITR-PT and ITR-LN were 21.77% and \u22120.88%, respectively. The optimal cut-off values for predicting prognosis were approximately 10% for ITR-PT (hazard ratio [HR], 3.23; 95% confidence interval [CI], 1.84\u20135.64) and \u221210% for ITR-LN (HR, 2.20; 95% CI, 1.27\u20133.80). ITR-PT showed a greater impact on RFS (3-year RFS: ITR-PT\u2009\u2265\u200910%, 66.1%; ITR-PT\u2009&lt;\u200910%, 18.4%; log-rank <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared with ITR-LN (3-year RFS: ITR-LN\u2009\u2265\u2009\u221210%, 64.1%; ITR-PT\u2009&lt;\u2009\u221210%, 34.3%; log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.004). Multivariate analysis of RFS identified ypN, ITR-PT, and ITR-LN as independent prognostic factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Both ITR-PT and ITR-LN are promising predictors of survival in patients with ESCC who underwent NAC-DCF plus surgery. ITR-PT may be a stronger prognostic factor than ITR-LN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10388-025-01128-5","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:59:09Z","timestamp":1745830749000},"page":"398-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial reduction of the primary tumor or lymph nodes: which is the better prognostic factor in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemotherapy followed by surgery?"],"prefix":"10.1007","volume":"22","author":[{"given":"Takaomi","family":"Hagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-5422","authenticated-orcid":false,"given":"Osamu","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masuhiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kohda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Hiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Imano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takushi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"3","key":"1128_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660. (Epub 2021 Feb 4. PMID: 33538338).","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1128_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9. (Epub 2011 Aug 31. PMID: 21879261).","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1128_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdw439","volume":"28","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Yasuda T, Yano M, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28(1):116\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdw439. (PMID: 27687307).","journal-title":"Ann Oncol"},{"issue":"2","key":"1128_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000452765","volume":"92","author":"O Shiraishi","year":"2017","unstructured":"Shiraishi O, Yamasaki M, Makino T, et al. Feasibility of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus adriamycin, cisplatin, and 5-fluorouracil for resectable advanced esophageal cancer. Oncology. 2017;92(2):101\u20138. https:\/\/doi.org\/10.1159\/000452765. (Epub 2016 Dec 2. PMID: 27907921).","journal-title":"Oncology"},{"issue":"13","key":"1128_CR5","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1245\/s10434-019-07744-7","volume":"26","author":"T Hagi","year":"2019","unstructured":"Hagi T, Makino T, Yamasaki M, et al. Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol. 2019;26(13):4754\u201364. https:\/\/doi.org\/10.1245\/s10434-019-07744-7. (Epub 2019 Aug 26. PMID: 31452051).","journal-title":"Ann Surg Oncol"},{"issue":"10447","key":"1128_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, JCOG1109 investigators, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1. (Epub 2024 Jun 11. PMID: 38876133).","journal-title":"Lancet"},{"issue":"3","key":"1128_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000528937","volume":"101","author":"O Shiraishi","year":"2023","unstructured":"Shiraishi O, Kato H, Momose K, et al. Impact of relative dose intensity of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy on survival of esophageal squamous cell cancer patients. Oncology. 2023;101(3):203\u201312. https:\/\/doi.org\/10.1159\/000528937. (Epub 2023 Jan 4. PMID: 36599320).","journal-title":"Oncology"},{"issue":"8","key":"1128_CR8","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1245\/s10434-014-4299-9","volume":"22","author":"T Yasuda","year":"2015","unstructured":"Yasuda T, Yano M, Miyata H, et al. Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)-positive lymph nodes following neoadjuvant chemotherapy and surgery for resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22(8):2599\u2013607. https:\/\/doi.org\/10.1245\/s10434-014-4299-9. (Epub 2014 Dec 19. PMID: 25524011).","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1128_CR9","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1245\/s10434-018-6507-5","volume":"25","author":"H Miyata","year":"2018","unstructured":"Miyata H, Tanaka K, Makino T, et al. The impact of pathological tumor regression and nodal status on survival and systemic disease in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25(8):2409\u201317. https:\/\/doi.org\/10.1245\/s10434-018-6507-5. (Epub 2018 May 10. PMID: 29748887).","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1128_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","volume":"273","author":"S Urakawa","year":"2021","unstructured":"Urakawa S, Makino T, Yamasaki M, et al. Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg. 2021;273(6):1141\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000003445. (PMID: 31274656).","journal-title":"Ann Surg"},{"issue":"6","key":"1128_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/SLA.0000000000004238","volume":"275","author":"T Hagi","year":"2022","unstructured":"Hagi T, Makino T, Yamasaki M, et al. Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery. Ann Surg. 2022;275(6):1121\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000004238. (Epub 2020 Jul 14. PMID: 32910622; PMCID: PMC10060043).","journal-title":"Ann Surg"},{"issue":"8","key":"1128_CR12","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1245\/s10434-024-15314-9","volume":"31","author":"T Hagi","year":"2024","unstructured":"Hagi T, Shiraishi O, Nakanishi T, et al. Utility of initial tumor reduction as a prognostic factor in esophageal squamous cell cancer patients undergoing neoadjuvant chemotherapy followed by surgery: a retrospective cohort study. Ann Surg Oncol. 2024;31(8):5064\u201374. https:\/\/doi.org\/10.1245\/s10434-024-15314-9. (Epub 2024 Apr 25. PMID: 38664331).","journal-title":"Ann Surg Oncol"},{"key":"1128_CR13","volume-title":"TNM classification of malignant tumors","author":"J Brierley","year":"2017","unstructured":"Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumors. 8th ed. Oxford: Wiley-Blackwell; 2017.","edition":"8"},{"issue":"1","key":"1128_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14(1):1\u201336. https:\/\/doi.org\/10.1007\/s10388-016-0551-7. (Epub 2016 Nov 10. PMID: 28111535; PMCID: PMC5222932).","journal-title":"Esophagus"},{"issue":"1","key":"1128_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10388-016-0556-2","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part ii and III. Esophagus. 2017;14(1):37\u201365. https:\/\/doi.org\/10.1007\/s10388-016-0556-2. (Epub 2016 Nov 10. PMID: 28111536; PMCID: PMC5222925).","journal-title":"Esophagus"},{"issue":"4","key":"1128_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10388-021-00831-3","volume":"18","author":"O Shiraishi","year":"2021","unstructured":"Shiraishi O, Makino T, Yamasaki M, et al. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. Esophagus. 2021;18(4):825\u201334. https:\/\/doi.org\/10.1007\/s10388-021-00831-3. (Epub 2021 Mar 18. PMID: 33738656).","journal-title":"Esophagus"},{"issue":"11","key":"1128_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41416-022-01726-5","volume":"126","author":"T Makino","year":"2022","unstructured":"Makino T, Yamasaki M, Tanaka K, et al. Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. Br J Cancer. 2022;126(11):1555\u201362. https:\/\/doi.org\/10.1038\/s41416-022-01726-5. (Epub 2022 Feb 9. PMID: 35140339; PMCID: PMC9130290).","journal-title":"Br J Cancer"},{"issue":"3","key":"1128_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343\u201372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2. (Epub 2023 Mar 18. PMID: 36933136; PMCID: PMC10024303).","journal-title":"Esophagus"},{"issue":"3","key":"1128_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","volume":"21","author":"S Mine","year":"2024","unstructured":"Mine S, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: part I. Esophagus. 2024;21(3):179\u2013215. https:\/\/doi.org\/10.1007\/s10388-024-01054-y. (Epub 2024 Apr 3. PMID: 38568243; PMCID: PMC11199297).","journal-title":"Esophagus"},{"issue":"3","key":"1128_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10388-024-01048-w","volume":"21","author":"Y Doki","year":"2024","unstructured":"Doki Y, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: part II. Esophagus. 2024;21(3):216\u201369. https:\/\/doi.org\/10.1007\/s10388-024-01048-w. (Epub 2024 Mar 21. PMID: 38512393; PMCID: PMC11199314).","journal-title":"Esophagus"},{"issue":"2","key":"1128_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026. (PMID: 19097774).","journal-title":"Eur J Cancer"},{"key":"1128_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2022.07.027","volume":"175","author":"S Lorenzen","year":"2022","unstructured":"Lorenzen S, Quante M, Rauscher I, et al. PET-directed combined modality therapy for gastroesophageal junction cancer: results of the multicentre prospective MEMORI trial of the German cancer consortium (DKTK). Eur J Cancer. 2022;175:99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.027. (Epub 2022 Sep 10. PMID: 36099671).","journal-title":"Eur J Cancer"},{"issue":"25","key":"1128_CR23","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.20.03611","volume":"39","author":"KA Goodman","year":"2021","unstructured":"Goodman KA, Ou FS, Hall NC, et al. Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (alliance) trial. J Clin Oncol. 2021;39(25):2803\u201315. https:\/\/doi.org\/10.1200\/JCO.20.03611. (Epub 2021 Jun 2. PMID: 34077237; PMCID: PMC8407649).","journal-title":"J Clin Oncol"},{"issue":"3","key":"1128_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3892\/mco.2013.89","volume":"1","author":"M Motoori","year":"2013","unstructured":"Motoori M, Yano M, Yasuda T, et al. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. Mol Clin Oncol. 2013;1(3):521\u20136. https:\/\/doi.org\/10.3892\/mco.2013.89. (Epub 2013 Mar 11. PMID: 24649204; PMCID: PMC3916104).","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"1128_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jso.20501","volume":"93","author":"H Akita","year":"2006","unstructured":"Akita H, Doki Y, Miyata H, et al. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol. 2006;93(5):401\u20139. https:\/\/doi.org\/10.1002\/jso.20501. (PMID: 16550577).","journal-title":"J Surg Oncol"},{"issue":"2","key":"1128_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijrobp.2019.10.019","volume":"106","author":"AS Grewal","year":"2020","unstructured":"Grewal AS, Min EJ, Long Q, et al. Early tumor and nodal response in patients with locally advanced non-small cell lung carcinoma predict for oncologic outcomes in patients treated with concurrent proton therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2020;106(2):358\u201368. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.019. (Epub 2019 Oct 22. PMID: 31654783).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1128_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1442-2050.2008.00879.x","volume":"22","author":"H Akita","year":"2009","unstructured":"Akita H, Doki Y, Yano M, et al. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus. 2009;22(4):291\u20137. https:\/\/doi.org\/10.1111\/j.1442-2050.2008.00879.x. (Epub 2008 Nov 19. PMID: 19021686).","journal-title":"Dis Esophagus"},{"issue":"7","key":"1128_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00595-013-0725-z","volume":"44","author":"H Yamada","year":"2014","unstructured":"Yamada H, Hosokawa M, Itoh K, et al. Diagnostic value of 18F-FDG PET\/CT for lymph node metastasis of esophageal squamous cell carcinoma. Surg Today. 2014;44(7):1258\u201365. https:\/\/doi.org\/10.1007\/s00595-013-0725-z. (PMID: 24077997).","journal-title":"Surg Today"},{"issue":"3","key":"1128_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2015.11.014","volume":"42","author":"K Parry","year":"2016","unstructured":"Parry K, Haverkamp L, Bruijnen RC, et al. Staging of adenocarcinoma of the gastroesophageal junction. Eur J Surg Oncol. 2016;42(3):400\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2015.11.014. (Epub 2015 Dec 6. PMID: 26777127).","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1128_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1590\/1806-9282.64.02.170","volume":"64","author":"J Li","year":"2018","unstructured":"Li J, Chen S, Zhu G. Comparative study of computed tomography (CT) and pathological diagnosis toward mediastinal lymph node metastasis in esophageal carcinoma. Rev Assoc Med Bras (1992). 2018;64(2):170\u20134. https:\/\/doi.org\/10.1590\/1806-9282.64.02.170. (PMID: 29641678).","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"1","key":"1128_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00330-017-4935-4","volume":"28","author":"J Liu","year":"2018","unstructured":"Liu J, Wang Z, Shao H, et al. Improving CT detection sensitivity for nodal metastases in oesophageal cancer with combination of smaller size and lymph node axial ratio. Eur Radiol. 2018;28(1):188\u201395. https:\/\/doi.org\/10.1007\/s00330-017-4935-4. (Epub 2017 Jul 4. PMID: 28677059).","journal-title":"Eur Radiol"},{"issue":"4","key":"1128_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ags3.12444","volume":"5","author":"H Shimada","year":"2021","unstructured":"Shimada H, Fukagawa T, Haga Y, et al. Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: a systematic review of the literature. Ann Gastroenterol Surg. 2021;5(4):404\u201318. https:\/\/doi.org\/10.1002\/ags3.12444. (PMID:34337289; PMCID:PMC8316742).","journal-title":"Ann Gastroenterol Surg"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-025-01128-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T07:01:49Z","timestamp":1749970909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-025-01128-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1007\/s10388-025-01128-5","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"type":"print","value":"1612-9059"},{"type":"electronic","value":"1612-9067"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent or substitute for it was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}